SK pharmateco – The pharma industry does not stand still… why should we?

Since SK pharmteco’s formation in 2019, through the combination of SK biotek Ireland, AMPAC Fine Chemicals (AFC)/AMPAC Analytical and SK biotek Korea, the company has integrated capacity and capability into a world-class CDMO. With over 1700 people and 9 facilities located across 3 continents, and primed for further expansion, SK pharmteco is well positioned to provide benefits and value to our clients across our global network.